Plasma GH is a biomarker candidate for predicting outcomes in advanced HCC patients treated with Atezo/Bev
A new research paper was published in Oncotarget's Volume 13 on December 6, 2022, entitled, "Plasma growth hormone is a potential biomarker of response to atezolizumab and bevacizumab in advanced hepatocellular carcinoma patients."
Source: news-medical.net